Fellowship · Chicago, IL
Sponsored by University of Illinois College of Medicine at Chicago · Director Amatur Amarah
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
The Lancet. Neurology · 2021 · 399 citations · Deepa Chand
Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia.
Hepatology international · 2025 · 73 citations · Nadim Mahmud
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19.
JAMA internal medicine · 2021 · 382 citations · Anand Srivastava, Ambarish Athavale
National Kidney Foundation Laboratory Engagement Working Group Recommendations for Implementing the CKD-EPI 2021 Race-Free Equations for Estimated Glomerular Filtration Rate: Practical Guidance for Clinical Laboratories.
Clinical chemistry · 2022 · 181 citations · Jennifer Ennis
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy.
Journal of hepatology · 2021 · 248 citations · Deepa Chand
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.
The Lancet. Neurology · 2021 · 228 citations · Deepa Chand
AKI Treated with Renal Replacement Therapy in Critically Ill Patients with COVID-19.
Journal of the American Society of Nephrology : JASN · 2021 · 211 citations · Anand Srivastava, Ambarish Athavale
Race, Genetic Ancestry, and Estimating Kidney Function in CKD.
The New England journal of medicine · 2021 · 199 citations · James Lash